Document Detail


Propranolol diminishes cardiac hypertrophy but does not abolish acceleration of the ischemic contracture in hyperthyroid hearts.
MedLine Citation:
PMID:  10975597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study was undertaken to define the contributions of left ventricular hypertrophy (LVH) and increased adrenergic activity to the acceleration of ischemic contracture (IC) that occurs in chronic hyperthyroid rat heart. Acute and chronic hyperthyroidism (THYR) were induced by thyroxine administration for 2 and 14 days, respectively, and normal animals (NORM) served as controls. Isolated hearts were perfused in a Langendorff mode. NORM alpha acute, n = 6; THYR alpha acute, n = 8; and THYR alpha, n = 13; and NORM alpha, n = 13 were subjected to 20-min zero-flow global ischemia (I) and 45-min reperfusion (R). Additional THYR and NORM hearts treated with propranolol (prop) were subjected to 30-min I; THYR beta prop, n = 6 and NORM beta prop, n = 8, and THYR beta, n = 6, NORM beta, n = 8 served as controls. Acceleration of IC was measured by the time to peak contracture (Tmax). Left ventricular hypertrophy (LVH) was assessed by the ratio of left ventricular weight in milligrams (LVW) to animal body weight (BW) in grams. Cardiac hypertrophy developed in chronic but not acute hyperthyroidism. Propranolol reduced the extent of LVH. Contracture occurred earlier in chronic than in acute hyperthyroid and normal hearts. Propranolol did not alter contracture. In conclusion, IC is accelerated by thyroxine administration, and this is probably not due to LVH or increased beta-adrenergic activity. Propranolol diminishes LVH in hyperthyroidism.
Authors:
C I Pantos; I S Mourouzis; S M Tzeis; V Malliopoulou; D D Cokkinos; P Asimacopoulos; H C Carageorgiou; D D Varonos; D V Cokkinos
Related Documents :
3057847 - The effects of a transtelephonic surveillance and prehospital emergency intervention sy...
998507 - Propranolol therapy in patients undergoing myocardial revascularization.
7302777 - Evaluation of lorcainide, a new anti-arrhythmic agent.
3246247 - Coronary vasomotor and therapeutic influences of propranolol and nifedipine on the spon...
24402027 - Remote ischaemic conditioning and ischaemic heart disease.
386607 - Hemodilution -- new clothes for an anemic emperor.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  36     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2001-01-02     Completed Date:  2001-01-02     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  384-9     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, University of Athens, Goudi, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology*
Animals
Glycogen / metabolism
Hyperthyroidism / physiopathology*
Hypertrophy, Left Ventricular / drug therapy*,  physiopathology
Male
Myocardial Contraction / drug effects*
Myocardial Ischemia / physiopathology*
Myocardial Reperfusion
Propranolol / pharmacology*
Rats
Rats, Wistar
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 525-66-6/Propranolol; 9005-79-2/Glycogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocar...
Next Document:  Effects of amphetamine on calcium and potassium currents in rat heart.